<DOC>
	<DOCNO>NCT00986037</DOCNO>
	<brief_summary>The primary purpose study determine safety , tolerability pharmacokinetics ABT-308 healthy volunteer patient mild moderate control asthma .</brief_summary>
	<brief_title>Assessment Safety ABT-308 Healthy Volunteers Subjects With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Healthy volunteer : 1 . A condition good health base upon result medical history , physical examination , vital sign , laboratory profile ECG . 2 . BMI 18 29 , inclusive . Mild asthma patient : 1 . Diagnosis wellcontrolled , mild moderate asthma GINA guideline &gt; = 6 month 2 . A condition good health ( mild moderate asthma ) base upon result medical history , physical examination , vital sign laboratory profile EDG . 3 . BMI 18 34 , inclusive . 1 . Asthma exacerbation within 8 week Study Day 1 . 2 . Clinically significant allergic reaction drug , biologic , food , vaccine . 3 . History allergic reaction significant sensitivity constituent study drug . 4 . Receipt investigational product within 30 day 5 halflives ( whichever longer ) prior study drug administration . 5 . Subject smoker history smoking within 6month period precede study drug administration . 6 . Current enrollment another clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Adverse event</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>